a complete list of recommendations, please refer to the Results section of the text. For the level of evidence supporting each recommendation, see Table 2 Very low Conditional recommendation based on very-low-quality evidence; may consider switching to a TNFi biologic and MTX combination therapy if the current TNFi biologic is infliximab. 12. Switch to an IL-17i biologic monotherapy over switching to an IL-17i biologic and MTX combination therapy (PICO 32) Very low Conditional recommendation